recent
editori
journal
american
medic
associ
suggest
muraglitazar
diabet
drug
develop
may
associ
unexplain
increas
rate
condit
associ
inflamm
stroke
heart
diseas
muraglitazar
act
bind
peroxisom
proliferatoractiv
receptor
ppar
specif
pparc
famili
addit
modul
insulin
sensit
activ
receptor
lead
acut
reduct
inflamm
propos
earlier
case
nonsteroid
antiinflammatori
agent
paradox
host
respons
chronic
muraglitazar
use
may
produc
compensatori
increas
level
inflamm
would
explain
heighten
cardiovascular
risk
paradox
longterm
sequela
arisen
two
class
drug
entir
distinct
mechan
action
find
suggest
effect
may
necessarili
aris
invok
specif
function
pathway
may
origin
instead
fundament
physiolog
respons
conclus
provid
greater
support
hypothesi
inde
consid
agent
conceptu
framework
mind
may
find
sourc
risk
exist
may
still
exist
mani
medic
paradigm
may
highlight
need
signific
chang
approach
tempor
dimens
treatment
question
exist
fli
respond
viru
produc
complet
vitro
use
revers
genet
viru
gener
way
also
call
infecti
clone
contain
contamin
sick
anim
translat
german
howev
pcr
use
identifi
virus
previous
sequenc
pna
paper
other
show
refer
composit
stock
viru
subbarao
et
al
referenc
eid
paper
claim
first
character
diseas
human
though
eid
studi
fail
detect
sever
diseas
organ
anomali
label
enigma
rather
contradict
robert
webster
correspond
author
pna
paper
director
collabor
center
studi
ecolog
influenza
anim
bird
inform
us
stock
virus
classifi
select
agent
liberti
releas
inform
without
verif
without
purif
describ
paper
accept
stock
viru
pure
fulli
character
inquiri
clarif
webster
cdc
select
agent
program
fli
receiv
respons
question
anim
pathogen
paper
describ
use
natur
rout
diseas
achiev
extraordinari
concentr
million
eid
per
anim
none
experi
use
control
blind
scienc
paper
highli
abstract
molecular
scienc
employ
elev
concentr
chimer
variant
question
human
pathogen
pandem
potenti
eid
paper
anecdot
report
boy
thailand
sever
multiorgan
diseas
evid
given
transmiss
human
scientist
found
evid
aspergillosi
boy
treat
toxic
agent
broadspectrum
antimicrobi
antivir
die
subbarao
et
al
referenc
eid
paper
describ
previous
healthi
hong
kong
boy
develop
flulik
symptom
may
treat
broadspectrum
antibiot
salicyl
acid
though
commonli
contraind
develop
rey
syndrom
die
eleven
day
later
search
commenc
causat
within
limit
rang
flu
virus
claim
caus
even
though
coronavirus
flavivirus
enterovirus
pathogen
chemic
also
caus
flu
symptom
confirm
prior
avian
contact
regardless
warn
explos
pandem
appear
earli
document
though
fli
conced
scientif
forecast
method
evalu
possibl
influenza
viru
induc
new
pandem
question
non
causat
neither
subbarao
et
al
studi
fli
refer
consid
reason
compet
theori
diseas
causat
eg
environment
pharmaceut
factor
analysi
show
paper
satisfi
four
basic
question
claim
pathogen
pandem
potenti
need
challeng
neoadjuv
chemotherapi
weekli
paclitaxel
breast
cancer
patient
may
increas
releas
cancer
cell
circul
decreas
interstiti
fluid
pressur
editor
paclitaxel
effect
agent
treatment
breast
cancer
green
et
al
report
result
random
trial
preoper
chemotherapi
compar
weekli
dose
paclitaxel
mgm
follow
four
cycl
fac
four
dose
paclitaxel
mgm
also
follow
four
cycl
fac
patient
oper
breast
cancer
patholog
complet
respons
rate
treat
weekli
paclitaxel
respect
p
moreov
superior
weekli
compar
everi
paclitaxel
term
respons
rate
time
progress
also
shown
metastat
breast
cancer
one
potenti
mechan
weekli
paclitaxel
antitumor
activ
frequent
deliveri
moder
dose
may
achiev
greater
efficaci
standard
paclitaxel
frequent
exposur
paclitaxel
may
enhanc
apoptot
antiangiogen
effect
taghian
et
al
studi
evalu
interstiti
fluid
pressur
ifp
oxygen
neoadjuv
chemotherapi
use
sequenti
paclitaxel
doxorubicin
patient
breast
cancer
tumor
cm
phase
ii
protocol
paclitaxel
administ
weekli
schedul
dose
mgm
nine
cycl
found
paclitaxel
significantli
decreas
ifp
increas
oxygen
wherea
doxorubicin
caus
signific
chang
recent
studi
pachmann
et
al
show
neoadjuv
chemotherapi
paclitaxel
breast
cancer
patient
caus
releas
breast
cancer
cell
circul
time
reduc
tumor
size
appli
combin
therapi
three
differ
phase
observ
first
declin
number
circul
tumor
cell
epirubicin
contain
part
regimen
follow
steep
increas
paclitaxel
treatment
subsequ
redecreas
third
regimen
combin
administ
assum
sinc
ifp
may
barrier
tumor
cell
enter
circul
weekli
paclitaxel
may
elimin
barrier
decreas
ifp
addit
sinc
circul
tumor
cell
correl
patient
outcom
weekli
paclitaxel
may
increas
anthracyclin
drug
concentr
tumor
tissu
level
decreas
ifp
give
weekli
paclitaxel
first
anthracyclin
sequenti
manner
neoadjuv
set
may
optim
schedul
breast
cancer
patient
